In Helicobacter pylori seropositive individuals, the subsequent risk of non-cardia gastric cancer development is frequently attributed to the infection agent. Although the link between inflammation and gastric cancer is formally recognized, the molecular basis of evading mechanisms of Helicobacter pylori from host immune system remains unclear. The aim of this study was to determine the effect of systemic factors in gastric cancer patients such as serum kynurenine to tryptophan ratios, neopterin, nitric oxide and urinary biopterin levels which may sustain the persistence of Helicobacter pylori seropositivity. This prospective randomized study involved 95 adults with gastric cancer and 108 cancer free patients with extradigestive diseases. Each group was assigned into two subgroups according to Helicobacter pylori IgG seropositivity. Exposure to Helicobacter pylori was detected by serum IgG test (ELISA). Serum tryptophan, kynurenine, neopterin and nitrite concentrations were measured. In simultaneous urinary samples, neopterin, biopterin, and creatinine levels were assayed. Significant decreases were found in serum tryptophan levels of both Helicobacter pylori seronegative and seropositive gastric cancer patients versus controls without malignant disease. However, marked increase in kynurenine/tryptophan was observed only in Helicobacter pylori seropositive cancer patients. Highly significant correlation between the serum neopterin and kynurenine/tryptophan indicated interferon gamma stimulated tryptophan degradation. Decrease in serum nitrite levels, and a parallel increase in urinary biopterin concentrations in Helicobacter pylori seropositive cancer cases might result from the excessive nitric oxide consumption due to reactive oxygen radical overproduction. Significantly higher kynurenine to tryptophan ratio and its correlation with increased neopterin levels suggested a role of tryptophan-degrading enzyme indoleamine 2,3-dioxygenase (IDO) and that persistence of Helicobacter pylori seropositivity might participate in enhanced immune tolerance of cancer patients.
Introduction
The International Agency for Research on Cancer, sponsored by the World Health Organization, has recently categorized Helicobacter pylori (H. pylori) infection as a class I carcinogen, based on evidence that this infection increases the risk of gastric cancer (1) .
Actually twelve studies with 1228 gastric cancer cases revealed that the overall matched odds ratios (ORs) for the association between H. pylori infection and the subsequent development of non-cardia gastric cancers attributed to H. pylori infection is 2.36 (95% confidence interval (CI): 1.98-2.81). A 5.9-fold increase in risk associated with H. pylori seropositive test has been estimated 10 years or more prior to diagnosis. Eventual increase in cancer-risk is 2.1-2.6-fold after ten-years when compared with samples that were collected less than 10 years before the development of cancer (2) . The persistent inflammation of the stomach induced by H. pylori infection can have consequences on the rest of the body. Recent studies showed that the immunological response against H. pylori is not only locally but there are also systemically evoked phenom-ena by host. Especially in the last few years, many studies have been performed on the implication of H. pylori in the pathogenesis of extra-gastric diseases (3) . It is now known that exposure to H. pylori and subsequent seropositivity is associated with an increasing number of cardiovascular, respiratory, extra-gastroduodenal digestive, neurological and miscellaneous autoimmune disorders (4) . Surprisingly, most people infected with H. pylori are asymptomatic, which suggests that additional factors are necessary for the development of H. pylori-associated diseases (5) .
Persistence of H. pylori is achieved through initial interactions between the bacterial adhesins and cellular receptors, through which H. pylori may avoid clearance by the immune system. This is accomplished by producing specific bacterial factors that stimulate selective expression of host genes, and by inducing an ineffective T-cell response (6) . Mononuclear phagocytes play a central role in early immune responses to bacteria, serving as an important source of pro-inflammatory mediators and as antigen presenting cells that are involved in the initiation of specific immunity. Similarly, H. pylori-derived soluble proteins activate the peripheral blood monocytes and lead to increased expression of the inflammatory cytokines (7) . While immune serum slightly enhances H. pylori uptake into macrophages, still a sufficient inoculum remains for recovery of viable H. pylori from macrophages (8) .
Actually, primary human monocytes have a higher capacity to kill certain strains of H. pylori. As mentioned above, in contrast to monocytes, viable H. pylori has been recovered from macrophages a 48-hour period after infection, without depending on strainspecific differences in bacterial survival and the virulence factors (9) . In this regard, H. pylori infection induces autophagosome formation, and these autophagic vesicles were adapted for the multiplication of H. pylori in the host. Thus, H. pylori evade the intracellular killing after phagocytosis (10) . Furthermore it has been shown that the antiphagocytic activity of H. pylori may explain the persistence of bacteria and its pathological consequences (11) .
Recently, it has been emphasized that some other additional components of the innate immune response attenuate the cellular immunity against H. pylori. Consequently, H. pylori infection causes nitrative DNA damage to gastric epithelial cells by inducing reactive nitrogen species (RNS) synthesis from inflammatory cells (12) . Although the link between inflammation and gastric cancer is formally recognized, the molecular basis of evading mechanisms of H. pylori from immune system remains unclear.
In fact, extracellular H. pylori can be killed by nitric oxide (NO) and peroxynitrite formed upon reaction with superoxide anion, both released from activated macrophages. However, H. pylori arginase competes with host cell inducible NO synthase (iNOS) for the common substrate L-arginine (L-Arg) and prevents NO production by host cells (13) . Bussiére et al. demonstrated that H. pylori induces iNOS and NO production in macrophages but in parallel there is induction of arginase generating ornithine, and of ornithine decarboxylase, generating polyamines. In this context, H. pylori stimulates spermine synthesis by the arginase-ornithine decarboxylase pathway that inhibits iNOS translation and NO production, leading to persistence of the bacterium and risk for gastric cancer (14) . H. pylori-induced inflammatory response would favour to secrete even more interferon-γ (IFN-γ) and development of cell-mediated immunity (15, 16) .
Indeed, stimulation with different purified H. pylori antigens results in the production of Th1-type cytokines from both CD4 + and CD8 + T cells isolated from the circulation of H. pylori-infected individuals. A significant contribution of CD8 + cells is determined for the production of IFN-γ in these patients (17) . Ledochowski et al. described that serum neopterin concentrations were not related to the presence/absence of H. pylori in the gut: Antibody seropositive patients had higher neopterin concentrations than seronegative patients, even when bacteria seems to be no longer present in the gut (18) . Such data indicated an activated T-cell-macrophage system. In parallel to neopterin production, IFN-γ also may induce tryptophan-(Trp)-degrading enzyme indoleamine 2,3-dioxygenase (IDO) as an antimicrobial activity. During the first phase of infections, IDO-mediated Trp depletion is predominantly antimicrobial whereas in the next stage it may inhibit T-cell growth and development (19) . Thomas and Stocker proposed a sequential defense mechanism for the immune response, in which IDO activity is a first-line of defense against invading cells, whereas iNOS activity is a component of a later line of defense against persistent inflammation (20) . These evidences raise the question as to how H. pylori are consistently able to evade these cellular and humoral immune responses. Regarding these assumptions, present study was designed to determine the effects of systemic factors such as serum kyurenine (Kyn) and Trp, serum neopterin, nitrite as an index for NO production, and urinary neopterin and biopterin levels, which may sustain the persistency of H. pylori seropositivity, in gastric cancer patients. (21), UBT was not available in this study. At the same time the 13 C-urea breath test is the ideal diagnostic tool to monitor eradication therapy in patients. However, findings suggest that infections with H. pylori may have a long-lasting impact on the cellmediated immune system even after viable bacteria has been radicated. Therefore H. pylori IgG seropositivity was aimed for our study. Thus exposure to H. pylori for each individual was determined by IgG serological test (H. pylori IgG ELISA, Demeditec, Kile-Wellsee, Germany). Both the control and gastric cancer groups, each were designated into two subgroups according to H. pylori IgG seropositivity. Taking into account the manual, individuals with H. pylori IgG titer below 8 U/ml were accepted as H. pylori seronegative, while the value above 12 U/ml was interpreted as H. pylori seropositive. The patients whose titer was between 8 and 12 U/ml were in the grey zone and not included into the study. There were 37 H. pylori IgG seronegative, 71 H. pylori IgG seropositive control patients, while 41 of the gastric cancer patients were H. pylori IgG seronegative and 54 were H. pylori IgG seropositive.
Patients and Methods

This
Cancer free patients had undergone diagnostic endoscopic evaluation whenever their complaints suggestive for digestive diseases. Patients in whom no pathology being found in upper or lower gastrointestinal system was included in cancer free control group. Neither of them had cardio-pulmonary or metabolic risks that could be an obstacle for surgery. Cancer free individuals were selected from the patient population who admitted to the hospital for hernioraphy, hemorroidectomy or breast biopsies.
The exclusion criteria for the study were to have immune system disorders, not to be able to receive surgical intervention or to receive neoadjuvant chemotherapy due to the late stage carcinoma, having neither malnutrition, autoimmune diseases, systemic inflammatory response syndrome, chronic granulomatosis, collagen tissue nor neurodegenerative diseases. The patients who fall into the grey zone in determination of H. pylori IgG seropositivity were excluded from the study groups. The patients who received traditional triple eradication therapy for H. pylori infection within the last two years were not included in this study groups.
All participants' rights were protected and informed consent was obtained according to the Helsinki Declaration. Local Ethic Committee approved the study protocol.
Peripheral venous blood from each individual was collected into one anticoagulant free blood collection tube and used for the serum separation. The urine specimens were collected coincidentally. All samples were obtained in the early morning, kept from direct light and kept in -20°C until assayed.
The neopterin, biopterin and creatinine levels in urine were analyzed by high performance liquid chromatography (HPLC). Within preanalytics no oxidation step was performed, thus only the endogenously formed species were determined. Neopterin and biopterin were isocratically seperated on reversed phase C18 columns with phosphate buffer eluent (15mM containing 2.5% methanol, pH 7.0) and quantified using a fluorescence detector (excitation at 353 nm, emission at 438 nm) where urinary creatinine concentrations were determined by ultraviolet detector (UV) at 235 nm, in the same chromatographic run (22) . Serum neopterin concentrations were determined by a commercially available enzyme immunoassay kit (ELISA, Tani Medical Laboratories, Ankara, Turkey) according to the manufacturer's instructions. The optical density was measured at 450 nm wavelength. Trp and Kyn concentrations in serum were determined by reversed-phase HPLC using RP18 and 15mM acetate buffer following precipitation of protein with trichloroacetic acid. Trp was measured via fluorescence detection at 285 nm excitation wavelength and 365 nm emission wavelength, while Kyn was detected by UV absorption at the 360 nm wavelength, simultaneously. In order to estimate the Trp degradation, Kyn to Trp ratio (Kyn/Trp) was calculated by dividing Kyn concentrations (µmol/L) by Trp concentrations (mmol/L) (23) . The frequencies of increased Kyn/Trp of H. pylori seronegative and seropositive colorectal cancer groups were estimated by comparing with the mean serum Kyn/Trp of H. pylori seronegative tumorfree patients. Serum nitrite concentrations were determined by using Griess method (24) . Serum nitrates measurements were not included in this study because nitrates are not the only final products of NO oxidation via nitrites, but could also be produced from peroxynitrites, formed in NO reaction with ROS. Therefore, serum nitrite level was accepted as conclusive profile of NO concentration (25) .
Statistical Analysis
Data were analysed using the statistical package SPSS, version 13.0 (SPSS Inc., Chicago, Illinois, USA). All results were expressed as the mean ± SEM. After checking the data by Kolmogorov-Smirnov test, non-parametric data of the two independent groups were compared with Mann-Whitney U-test and p <0.05 was considered statistically significant. Correlations were assessed using Spearman's rank test.
Results
Trp concentrations in cancer patients were significantly lower than that of cancer-free controls (U = 2899, p = 0.0001). The concentration of first detectable product of Trp degradation pathway, Kyn were only slightly higher but not significantly different in tumor-free patients. Still gastric cancer patients showed a significant rise in Kyn/Trp ratio (U = 3373, p = 0.013) (Figure, Table 1 ). The data based on H. pylori seronegative subgroups, demonstrated that there was no significant difference in serum Kyn and Kyn/Trp between the cancer-free and gastric cancer patients. However, there was a significant decrease in serum Trp levels of H. pylori seronegative gastric cancer patients (U = 379, p = 0.006) ( Table 2 ). It may be mostly due to cancer development. In H. pylori seropositive group, in addition to reduced serum Trp concentrations (U = 1158, p = 0.009), a significant rise in serum Kyn/Trp (U = 1216, p = 0.02) was observed (Figure, Table 3 ) , respectively) . Similarly, the correlation in the same parameters of H. pylori seronegative and seropositive cancer patients were also significant (r s = 0.362, p = 0.028 and r s = 0.339, p = 0.020, respectively). Also urinary neopterin and serum neopterin levels were significantly correlated in H. pylori seronegative and seropositive gastric cancer groups. Serum nitrite concentrations were significantly decerase in gastric cancer patients (U = 3547, p = 0.0001) ( Table 1) . Although the serum nitrite levels were significantly lower in H. pylori seropositive cancer patients compared to H. pylori seropositive cancerfree matched controls (U = 1214, p = 0.001) (Table 3) , nitrite levels did not differ between H. pylori seronegative cancer group and matched controls (U = 600, p = 0.113) ( Table 2) .
Highly significant increase in urinary biopterin was observed in H. pylori seropositive gastric cancer patients (U = 622, p = 0.001), and there were significant correlations between urinary neopterin and 
Discussion
It is well known that there is an ongoing risk for developing gastric cancer even after the cure of H. pylori infection and extinction of gastric inflammation (26) . Therefore the other histological findings were ignored in our series of patients because of high seroprevalence of H. pylori in general population and prevalent asymptomatic infection makes it difficult to interpret histological findings for the definite role of H. pylori (27) .
Although H. pylori has been recognized as a class I human carcinogen, the bacterium does not induce carcinogenesis by itself. The present scientific consensus is that the bacterial oncogenic role is mediated by the chronic active inflammation. Strongly suggestive evidences point to oxidative stress as having a pivotal role in the development of cancer (28) .
Alteration in the activity of ROS-scavenging enzymes by the presence of H. pylori may in part be responsible for the increased risk of gastric cancer in H. pylori-infected individuals. In these cases, rising in antioxidant enzyme activities is associated with reduced susceptibility of human gastric cells to lethal injury (29) . Detection of ROS in antral mucosal biopsy specimens suggested that excess mucosal ROS production is associated with H. pylori infection and may be an important pathogenic mechanism (30) .
While ROS-releasing phagocytic leukocytes recruited to the gastric mucosa during H. pylori infection represent one of the obvious sources of oxidative stress (30, 31) , H. pylori itself also generates ROS. Additionally, H. pylori infection has been shown to increase expression and activity of spermine oxidase, which oxidizes polyamines that are abundant in epithelial cells to release hydrogen peroxide (32) . iNOSmRNA levels are significantly upregulated in the cells infected with H. pylori. Increased NO production in the gastric epithelial cells is seen as early as 18h after exposure to H. pylori, and subsequent maximal levels are obtained within 24h (33) . Afterwards, NO might be rapidly trapped by superoxide radicals in and around H. pylori, forming peroxynitrite. Consistent with this notion is the finding that intracellular peroxynitrite, similar to NO, irreversibly inhibits the respiration of H. pylori (34) .
Excessive ROS and RNS production in the H. pylori-infected stomach by activated neutrophils and H. pylori itself can damage DNA in gastric epithelial cells, implying its involvement in gastric carcinogenesis (35) . NO and superoxide can antagonize each other's biological actions in regard to NO / superoxide balance in cytoplasmic fraction (36) . The relative NO production rates have an impact on the NO mediated toxic versus protective effects (37) . Peroxynitrite formed in vivo from superoxide and NO can mediate (38) . In this process two-electron oxidation of peroxynitrite with thiols induces the formation of thiyl radicals that initiates an oxygen-dependent radical chain reaction. This could greatly amplify electron oxidation pathway in promoting peroxynitritedependent cellular oxidative stress (39) . Thus, H. pylori may induce oxidative stress by different mechanisms.
There is conflicting evidence about the role of NO in tumour development. Some researchers indicated an inverse relation between NO synthesis and gastric cancer. Increased synthesis of NO in gastric cancer supports the immune system by extending the necrosis of tumour tissues. In contrast, decrease of NO in tumour tissue might conduce to the tumour cells escape from apoptosis and preserve their reproducing ability (40) . However, recent studies showed an increase in NO expression of gastric cancer (41, 42) . Indeed the prognosis of gastric cancer patients whose tumors expressed iNOS were established to be significantly worse than those whose tumors did not express iNOS.
In our study, while serum nitrite levels were significantly lower in H. pylori seropositive cancer patients, no difference was found between H. pylori seronegative cancer patients and their H. pylori seronegative matched controls. A negative correlation between the amount of superoxide radicals and nitrite suggests that NO has antioxidative effects at site of injury (43) . Thus, the nitrite-NO pathway might be viewed as a backup system, to ensure suficient NO generation along the entire physiological oxygen gradient (44) . Decrease of serum nitrite in H. pylori seropositive cancer patients might be attributed to the relatively effective scavenging of the radicals by NO. Consequently, reduction of NO most probably might be due to the formation of peroxynitrite and other RNS, rather than reducing iNOS expression of cancer tissue or inflammatory cells. However, the scope of our study did not include the measurements of enzyme expression or activities, amino acid and NO levels in antral mucosal biopsy specimens. It seems that presence of H. pylori causes a significant increase in NO consumption by formation of redox active radicals in cancer cases. Likewise, we could not find any difference between the serum nitrite levels of H. pylori seronegative gastric cancer cases and their matched controls. This explanation consisted with the high urinary biopterin excretion, oxidized metabolite of 5,6,7,8-tetrahydrobiopterin (H4-bip). H4-bip is an indispensable cofactor for NO generation of iNOS (45) . Amount of intracellular H4-bip is critical for iNOS-dependent generation of NO (44) . Many types of cells produce H4-bip upon stimulation with IFN-γ (47) . Under conditions of increased oxidative stress, H4-bip plays a protective role for NOS against ROS, while being oxidized to biopterin (48) .
In our study, significant rise in urinary biopterin concentrations indicated that IFN-γ-induced guanosine triphosphat (GTP) cyclohydrolase I activities largely supported H4-bip synthesis in both either H. pylori seronegative or H. pylori seropositive gastric carcinoma patients. H4-bip but not biopterin production should relate to higher synthesis rate of nitrite. The findings that biopterin levels are higher but nitrite lower are lower in gastric cancer patients vs. controls forces us to conclude that H4-bip as well as NO may suffer from exposure to ROS, most probably NO combines with reactive oxygen metabolites to form RNS, such as nitrogen dioxide and peroxynitrite hereby NO bioavailability was decreased. Dihydroneopterin and H4-bip were shown to be equally potent feedback inhibitors of GTP cyclohydrolase I (49). However, GTP cyclohydrolase I activities correlates with the sum of neopterin plus biopterin rather than with neopterin or biopterin alone (47) .
H. pylori-stimulated iNOS protein translation and NO production are entirely dependent on the L-Arg concentration. Furthermore, limitation of L-Arg availability inhibits iNOS translation and thus attenuates killing of H. pylori (50) . Actually, no protein that is encoded by the H. pylori chromosome, is involved in the L-Arg biosynthetic pathways. Therefore L-Arg is not synthesized by H. pylori and the bacterium must obtain this amino acid from extracellular sources (51) . On the other hand, arginase enzymes are the endogenous antagonists of iNOS because they compete for the same substrate by metabolizing L-Arg into urea and Lornithine (52, 53) . Extracellular H. pylori can be killed by NO released from activated macrophages. However, arginase in the H. pylori competes with host cell iNOS for the common substrate L-arginine and prevents NO production by host cells (54) .
As mentioned above, one or more of these mechanisms might be responsible from reducing serum NO concentrations of H. pylori seropositive cancer patients. Actually, we supposed that the decrease in serum nitrite concentrations in gastric cancer group most probably may depend on the enhanced oxidative stress induced by H. pylori.
In the present study, significant increase in mean serum neopterin concentrations of overall cancer patients indicated appropriate response of macrophages against the cancer development without depending on the exposure of H. pylori. The average serum neopterin level of the non-tumor group was below the standard cutoff value, 10 nmol/L (55). In the evaluation of subgroups, the data demonstrated that there were no significant differences in serum and urinary neopterin concentration of both H. pylori seronegative and seropositive cancer patients compared to their matched controls. There was no significant difference between the serum neopterin levels of controls and cancer group because serum and urinary neopterin levels did not correlate in gastric cancer patients. However, urinary neopterin significantly correlated with serum neopterin in both H. pylori seronegative and seropositive cancer patients. Both the increases in urinary biopterin excretion and Kyn/Trp in H. pylori seropositive cancer patients compared to matched controls suggested that IFN-γ-mediated response may be enhanced by H. pylori. The formation of Kyn derivatives and nicotinamide adenine dinucleotides initiated by the enzymes tryptophan 2,3-dioxygenase (TDO) and IDO. Whereas TDO is merely located in the liver cells, IDO is expressed in a large variety of cells and is inducible by the cytokine IFN-γ (56). IDO activity is characterized best by the Kyn to Trp ratio which correlates with concentrations of immune activation markers such as neopterin (57) . Indeed, in our study highly significant correlation between neopterin concentrations with the increased Kyn/Trp clearly indicated that the formation of Kyn is related to IDO activity by IFN-γ stimulation. It is postulated that IDO limits immune cell proliferation by depleting locally available L-Trp and/or producing its cytotoxic metabolites (58, 59) . IDO is induced by IFN-γ in many human cell types and the depletion of L-Trp in the cellular microenvironment is partially responsible for the antiproliferative activities of IFN-γ (60, 61) . IDO has also been implicated in immunotolerance because it can inhibit the immune response, either by exhausting L-Trp in the medium or producing toxic metabolites that can cause apoptosis in T cells (62). In our study both H. pylori seronegative and H. pylori seropositive cancer cases showed significant decrease in serum Trp concentrations uniformly compared to their matched controls. Although the BMI of all patients were in normal range, in cancer free patients serum Trp levels were measured as 20.6±0.61µM which might be due to methodology. However, mean serum Kyn/Trp was showed a significant increase in H. pylori seropositive cancer patients only. Actually, NO regulates IDO activity biphasically, in a dose-dependent manner in such a way that, while high concentrations of NO production inactivates IDO enzyme and favors the immune response, low concentrations of NO increases IDO activity, so that IDO can participate in immune tolerance (63) . Consequently, IDO expression has thus been proposed as a possible mechanism facilitating induction of immune tolerance towards cancer (61) . Presence of H. pylori seropositivity might cause a rise in increased frequency of IDO activity by 13 percent in gastric cancer group. All these results suggested that IDO activities might be induced by H. pylori seropositivity in cancer patients. However, it was not investigated whether H. pylori colonization is still positive or not in these 54 gastric cancer cases. Moreover majority of these series of patients were in advanced stages. In our study, significantly higher Kyn/Trp and siginificant correlation between the Kyn/Trp and serum neopterin in addition to reduced nitrite concentrations in H. pylori seropositive cancer patients suggested that H. pylori might support the immune tolerance leading to cancer. Furthermore, the significant rise in increased frequency of Kyn/Trp was also a supportive finding for H. pylori seropositivity-induced immune tolerance in gastric cancer group. As a conclusion, H. pylori seropositivity in gastric cancer patients causes serious metabolic alterations which may facilitate the tumor progression irrespective of histopathological parameters.
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